Synapse - Renier Brentjens

Results (286)

Tumor-targeted human CD4(+) CD25(hi) regulatory T cells effectively inhibit T cell-mediated rejection of CD19(+) tumors in an in vivo xenotransplant tumor model

Meeting Abstract

Lee, J.; Sadelain, M.; Brentjens, R. J.
Blood (2008)

Fulltext@MSK | Save

Small molecule inhibition of Cdc7, a key cell cycle regulator and novel therapeutic target, successfully inhibits leukemia cell growth in vitro and in vivo

Meeting Abstract

Frattini, M. G.; Shum, D.; O'dwyer, K. M.; Brentjens, R. J.; Yeh, R.; Maslak, P.; Heaney, M. L.; Jurcic, J.; Djaballah, H.; Kelly, T. J.
Blood (2008)

Fulltext@MSK | Save

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors

Journal Article

Zakrzewski, J. L.; Suh, D.; Markley, J. C.; Smith, O. M.; King, C.; Goldberg, G. L.; Jenq, R.; Holland, A. M.; Grubin, J.; Cabrera-Perez, J.; more...
Nature Biotechnology (2008)

Fulltext@MSK | Save

Response -- Clinical application of a retroviral gene transfer protocol based on centrifugation-mediated vector preloading

Journal Article

Brentjens, R.; Riviere, I.; Sadelain, M.
Human Gene Therapy (2008)

Fulltext@MSK | Save

Enhanced anti-tumor efficacy of genetically modified T cells through the up-regulated expression of CD154 (CD40L)

Meeting Abstract

Seinstra, B.; Nikhamin, Y.; Brentjens, R.
Human Gene Therapy (2007)

Fulltext@MSK | Save

Efficacy and long term survival of genetically modified T cells targeting CD19 in a syngeneic immune competent transgenic murine tumor model is dependent on prior lymphodepleting chemotherapy

Meeting Abstract

Lee, J.; Nikhamin, Y.; Imperato, G.; Cohen, A.; Sadelain, M.; Brentjens, R.
Blood (2007)

Fulltext@MSK | Save

Pentostatin, cyclophosphamide, rituximab, and mitoxantrone (PCRM): A new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR